The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations
about
Proteopedia - a scientific 'wiki' bridging the rift between three-dimensional structure and function of biomacromoleculesA beta version of life: p110β takes center stageShould individual PI3 kinase isoforms be targeted in cancer?Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functionsNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyThe PI3K pathway as drug target in human cancerRapamycin and mTOR kinase inhibitorsEmerging common themes in regulation of PIKKs and PI3KsComprehensive genomic characterization defines human glioblastoma genes and core pathwaysWill kinase inhibitors make it as glioblastoma drugs?Phosphoinositides: tiny lipids with giant impact on cell regulationPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesThe Key Role of Calmodulin in KRAS-Driven AdenocarcinomasStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaInvestigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutantStructure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and SelectivityA frequent kinase domain mutation that changes the interaction between PI3K and the membraneThe p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsStructural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 proteinShaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34Structure of the iSH2 domain of human phosphatidylinositol 3-kinase p85β subunit reveals conformational plasticity in the interhelical turn regionRegulation of lipid binding underlies the activation mechanism of class IA PI3-kinasesAutoinhibition and Phosphorylation-Induced Activation of Phospholipase C-γ IsozymesDiscovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of RapamycinCrystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors DesignEngineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug designMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerPI3K mutations in breast cancer: prognostic and therapeutic implicationsPIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataSignaling by the phosphoinositide 3-kinase family in immune cellsS9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeletonPrioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing DataComprehensive assessment of cancer missense mutation clustering in protein structuresHigh throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibPI3K pathway alterations in cancer: variations on a themeTargeting the phosphoinositide 3-kinase pathway in cancerAssembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer.PI3K and cancer: lessons, challenges and opportunitiesMechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.The determinants of head and neck cancer: Unmasking the PI3K pathway mutations
P2860
Q21183903-50810B56-9CDA-476E-98FE-3B2D18091B71Q24293200-F80F0DF1-3294-4D9E-B909-8942A93D6E0AQ24309044-E029801A-50DB-4637-8189-A3D36D4E756AQ24339544-CA9F1806-5576-497A-AD20-65BFE85ADB6BQ24628724-4DEC1783-4547-4130-86AE-E1E0E287F816Q24632283-18D5C39F-EBB6-44C4-AC30-36C7C44933D5Q24644623-C916DD38-8F8D-472D-A604-2B7511531DD0Q24647293-4F8CA6A7-C053-4C3F-AB07-284D60DA7A61Q24656128-480848C1-EBB2-41DD-85F8-60F188143AE2Q27012684-217F28DC-32CF-4002-8382-4C467CC2EDCAQ27012953-58246015-4DCE-4EA7-B00E-92E36BB1C66FQ27015224-50574998-6CA6-40C5-8B1E-FCB9AA9975B5Q27021883-92911B60-5B88-4C99-A804-6FB7623FB39AQ27026544-9D87BEDC-ED79-413C-9AA4-5537DFFF32D6Q27320874-521AD41F-AC11-4582-ACBC-ED0E4DF086F2Q27650628-28351A3E-C397-4ED6-B0B1-E5DC2FD01E8EQ27657679-E3013DCD-DCD0-4143-B7FF-DE0F0C88C3D0Q27659013-95503CE3-6610-4BB3-99C3-937BA53AB32EQ27659586-1B11A070-05FE-4B8E-AF5F-2CE099657CFEQ27660331-0068490E-2EFE-4A97-9A16-462931B96B67Q27666219-2C228238-F9E6-451A-9DAD-C977FAF212E0Q27675831-AF1ACEB8-E16D-4E18-9AFD-A60EE220E77EQ27678692-B2ACA436-4B3E-4A40-AC0B-BA74862643D5Q27684091-7A10420D-43D7-42C3-9CC2-691323AB1126Q27684223-DD8DE16F-D76C-450A-9BB8-3860F15D84DCQ27684749-1486C4B3-B614-4FB9-ABB5-51DC88496BFDQ28076490-4BA76004-6CDF-4C31-B225-4F1EF6DC2833Q28081992-6A05C6D8-99C9-4C41-8B27-4BF215049B66Q28247338-A06F4DCA-EEA6-44C8-8EBE-1DC2690F54ABQ28283677-833DFB70-CE77-47FD-AF3B-0876C0895FE3Q28475032-855ADC3F-9230-4D94-998E-946D5F852048Q28534371-AE4E29A4-8D1E-4470-9E00-2971D47C9714Q28606437-5DDF5815-8CD9-47C2-970B-B027689B817BQ28818948-A661830D-B905-4B4E-A898-692A3D5A8052Q29615530-81AE3B99-A1C1-46D1-A59F-A0F5F0A33A1CQ29615809-83754582-F29F-411B-9BBB-86112A38D3D4Q30009083-10662535-91B6-47A4-8C59-3CB86B23D430Q30080017-AF22B801-00D8-487B-925E-C3524AD1055AQ30157667-E8140F5D-EB48-4E77-BF92-F55E12F4C19AQ30365726-75F638D6-1F25-4328-8394-CDAAB2503E7D
P2860
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@ast
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@en
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@nl
type
label
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@ast
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@en
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@nl
prefLabel
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@ast
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@en
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@nl
P2860
P50
P3181
P356
P1433
P1476
The structure of a human p110a ...... oncogenic PI3Kalpha mutations
@en
P2093
Diana Mandelker
Oleg Schmidt-Kittler
P2860
P304
P3181
P356
10.1126/SCIENCE.1150799
P407
P50
P577
2007-12-14T00:00:00Z